|Home page  | Editorial   | Journal  |  Guidelines to authors |  Contact  |

Acta Medica Medianae
Vol. 47, No3 , December, 2008
UDK 61
YU ISSN 0365-4478


Correspondence to:
Ana Antić

Zavod za transfuziju krvi

Bulevar dr Zorana Đinđića 48

18000 Niš, Srbija














Copyright 2008 by Faculty  of Medicine, University of Nis

Original article




Ana Antic, Sladjana Filipovic, Ivica Pejcic and Svetislav Vrbic



Retrospectively, we analyzed the use of blood products in Oncological Clinic of Clinical Centre Nis in the period November 1st 2007-November 1st 2008, and also the influence of the treatment on degree of anemia and thrombocytopenia and use of blood products. None of the patients received the whole blood. In this period, 324 patients received the transfusion of blood components, 302 patients received 983 units of red cells (red blood cell concentrate, resuspended, washed, filtered), 17 patients received 5050 ml of platelets (single-donor concentrate or pooled platelet concentrate) and 5 patients received 2200 ml of fresh frozen plasma. An average use of red cell transfusion is 3,26 units, platelet concentrate 5,54, fresh frozen plasma 2 units per oncological patient who receives transfusion. The use of red cell units and platelet concentrate transfusion was adequate (91,85% of patients received transfusion of red cells when Hgb<70g/l, 89,2% of patients received platelet concentrate transfusion when platelet count was less than 20 x109/l). During radio and chemotherapy we noticed a decrease of hematological parameter values, whereas the experimental group patients were dependant on blood product transfusion. Statistically, a significant decrease of hemoglobin level and platelet count was observed in the patients treated only with radiotherapy, who are the greatest consumers of blood products. Acta Medica Medianae 2008;47(4):13-18.


Key words: radiotherapy, chemotherapy, anemia, thrombocytopenia, component transfusion therapy

Fulll text